Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 3 institutions in 2 countries.
Gajendra W SuryawanshiDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-6143-7375
Jing WenDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-6127-6276
Saki ShimizuSchool of Nursing, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0003-4579-568X
Hubert ArokiumDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0001-9612-6350
Yiming XieDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Eugene WangDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Shihyoung KimDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.
Hyewon ChoiDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-2971-2250
Chong ZhangDivision of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84108, USA.
Hannah YuDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-5354-7622
Angela P PressonDivision of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84108, USA.ORCID 0000-0001-7400-3923
Namshin KimGenome Editing Research Center, Korea Research Institute of Biosciences and Biotechnology, Daejeon 34141, Republic of Korea.ORCID 0000-0001-6361-274X
Dong-Sung AnUCLA AIDS Institute, Los Angeles, CA 90095, USA.
Irvin S Y ChenDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0003-1199-2415
Sanggu KimDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0003-1228-6168
University of California, Los Angeles · USThe Ohio State University · USUniversity of Utah · US
Funding
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
Viral Immunology CoreU19AI117941 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SYMONDS, GEOFFREY · 2015 to 2019
$10.6M
In Vivo Gene Editing for HIV-1 CureR01AI145038 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, IRVIN S.Y. · 2019 to 2023
$3.4M
On-site, high-fidelity target sequencing and absolute quantitation for HIV-1 surveillanceR01HG010318 · NHGRI · OHIO STATE UNIVERSITY · PI KIM, SANGGU · 2018 to 2021
$2.9M
Hematopoietic stem/progenitor cell reservoirsR01AI110297 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, IRVIN S.Y. · 2014 to 2018
$1.9M
Genetic protection of hematopoietic stem cells for stable HIV controlR01AI100652 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AN, DONG SUNG · 2012 to 2016
$1.9M
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modificationR01HL125030 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, IRVIN S.Y. · 2014 to 2017
$1.5M
Defining a therapeutic threshold in HSPC gene therapy for HIV-1 diseaseR00HL116234 · NHLBI · OHIO STATE UNIVERSITY · PI KIM, SANGGU · 2016 to 2018
$747k
High-accuracy, long-range sequencing for HIV-1 genotypingR21HG010108 · NHGRI · OHIO STATE UNIVERSITY · PI KIM, SANGGU · 2018 to 2020
$624k
Mouse and mathematical models for HIV-1 suppression through HSPCR56HL126544 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, IRVIN S.Y., CHOU, TOM · 2014 to 2014
$381k
Defining a therapeutic threshold in HSPC gene therapy for HIV-1 diseaseK99HL116234 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KIM, SANGGU · 2012 to 2013
$178k
Modulating AhR in tumor and lymphoid microenvironments via local drug deliveryF32CA180586 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SZETO, GREGORY LEE · 2013 to 2014
Despite advances in hematopoietic stem/progenitor cell (HSPC) transplant for HIV-1-infected patients, the impact of a preexisting HIV-1 infection on the engraftment and clonal repopulation of HSPCs remains poorly understood. We have developed a long terminal repeat indexing-mediated integration site sequencing (LTRi-Seq) method that provides a multiplexed clonal quantitation of both anti-HIV-1 RNAi (RNA interference) gene-modified and control vector-modified cell populations, together with HIV-1-infected cells-all within the same animal. In our HIV-1-preinfected humanized mice, both therapeutic and control HSPCs repopulated efficiently without abnormalities. Although the HIV-1-mediated selection of anti-HIV-1 RNAi-modified clones was evident in HIV-1-infected mice, the organ-to-organ and intra-organ clonal distributions in infected mice were indistinguishable from those in uninfected mice. HIV-1-infected cells showed clonal patterns distinct from those of HSPCs. Our data demonstrate that, despite the substantial impact of HIV-1 infection on CD4
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The clonal repopulation of HSPC gene modified with anti-HIV-1 RNAi is not affected by preexisting HIV-1 infection. · full record | OpenQuestion